Literature DB >> 8641781

Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice.

H Frasa1, B Benaissa-Trouw, L Tavares, K van Kessel, M Poppelier, K Kraaijeveld, J Verhoef.   

Abstract

To study antibody-mediated protection against Escherichia coli peritonitis in BALB/c mice, monoclonal antibodies (MAbs) were generated against the capsule (K5) and the lipopolysaccharide (O18) of E. coli. Flow cytometric analysis with two selected immunoglobulin M MAbs revealed that bacteria were antigenically heterogeneous. Arbitrarily, three subpopulations in E. coli O18K5 cultures could be distinguished by double immunofluorescence. A subpopulation bound only the anti-K5 MAb, and another subpopulation bound only the anti-O18 MAb. An intermediate subpopulation, however, bound both MAbs. In agreement with this result, combinations of both MAbs enhanced phagocytosis of fluorescein isothiocyanate-labeled bacteria by human polymorphonuclear leukocytes and mouse macrophage J774 cells as well. In protection experiments, combinations of both MAbs, preincubated with 3 50% lethal doses of E. coli O18K5, protected all mice upon intraperitoneal challenge. Relatively high doses of either MAb alone proved to be not fully protective in this infection model. Protection of mice by the combination of MAbs was associated with significantly lower (P < 0.02) tumor necrosis factor levels in serum 90 min after challenge compared with any other treatment group. Similarly, prophylactic administration of MAbs yielded significantly lower (P < 0.01) tumor necrosis factor levels in mice that received the combination of MAbs than in any other treatment group.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641781      PMCID: PMC173837          DOI: 10.1128/iai.64.3.775-781.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Phagocytosis and cytolysis by a macrophage tumour and its cloned cell line.

Authors:  P Ralph; I Nakoinz
Journal:  Nature       Date:  1975-10-02       Impact factor: 49.962

2.  Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo.

Authors:  K S Kim; J H Kang; A S Cross; B Kaufman; W Zollinger; J Sadoff
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

3.  The importance of the K1 capsule in invasive infections caused by Escherichia coli.

Authors:  A S Cross; P Gemski; J C Sadoff; F Orskov; I Orskov
Journal:  J Infect Dis       Date:  1984-02       Impact factor: 5.226

4.  Phagocytosis of bacteria by human leukocytes measured by flow cytometry.

Authors:  C F Bassøe; O D Laerum; C O Solberg; B Haneberg
Journal:  Proc Soc Exp Biol Med       Date:  1983-11

5.  Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli.

Authors:  A S Cross; K S Kim; D C Wright; J C Sadoff; P Gemski
Journal:  J Infect Dis       Date:  1986-09       Impact factor: 5.226

6.  Escherichia coli in bacteremia: O-acetylated K1 strains appear to be more virulent than non-O-acetylated K1 strains.

Authors:  H Frasa; J Procee; R Torensma; A Verbruggen; A Algra; M Rozenberg-Arska; K Kraaijeveld; J Verhoef
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

7.  Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1.

Authors:  G Pluschke; M Achtman
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

8.  Role of the capsule and the O antigen in resistance of O18:K1 Escherichia coli to complement-mediated killing.

Authors:  G Pluschke; J Mayden; M Achtman; R P Levine
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

9.  Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli.

Authors:  A S Cross; W Zollinger; R Mandrell; P Gemski; J Sadoff
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

10.  Escherichia coli O18ac antigen: structure of the O-specific polysaccharide moiety.

Authors:  D S Gupta; B Jann; K Jann
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

View more
  5 in total

1.  Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection.

Authors:  T Rukavina; B Tícac; M Susa; N Jendrike; S Jonjíc; P Lucin; R Marre; M Doríc; M Trautmann
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

2.  Binding to and opsonophagocytic activity of O-antigen-specific monoclonal antibodies against encapsulated and nonencapsulated Klebsiella pneumoniae serotype O1 strains.

Authors:  T K Held; N R Jendrike; T Rukavina; R Podschun; M Trautmann
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

3.  Effect of imipenem on monoclonal antibody-mediated protection against Escherichia coli O18K5.

Authors:  H Frasa; B Benaissa-Trouw; L Tavares; K van Kessel; W Hustinx; J Schellekens; K Kraaijeveld; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

4.  Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.

Authors:  Kendra N Iskander; Marcin F Osuchowski; Deborah J Stearns-Kurosawa; Shinichiro Kurosawa; David Stepien; Catherine Valentine; Daniel G Remick
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

5.  Proinflammatory cytokines in antilipopolysaccharide immunity against Klebsiella infections.

Authors:  Tomislav Rukavina; Vanja Vasiljev; Brigita Ticac
Journal:  Mediators Inflamm       Date:  2005-06-09       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.